ANNA BALABAN: Open Payments
NPI 1750917076 · ATLANTA, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,241 in 48 payments from 22 companies in 2025. Trend: 2023 $287 · 2024 $1,606 · 2025 $1,241
Food & beverage: $1,241
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 7 | $279 |
| Daiichi Sankyo Inc. | 5 | $117 |
| Incyte Corporation | 4 | $103 |
| Novartis Pharmaceuticals Corporation | 5 | $96 |
| TerSera Therapeutics LLC | 2 | $69 |
| GENZYME CORPORATION | 2 | $66 |
| Merck Sharp & Dohme LLC | 2 | $56 |
| Janssen Biotech, Inc. | 2 | $49 |
| Exelixis Inc. | 2 | $48 |
| Genentech USA, Inc. | 2 | $45 |
Products named: ENHERTU, DATROWAY, MONJUVI, Zoladex, SARCLISA, CABOMETYX, Vanflyta, LUTATHERA.
Industry payments across GA — which companies pay providers there.
